Related Experiment Videos
[Plasma Nt-proBNP concentration during heart failure therapy].
Lin Wang1, Wen-ling Zhu, Lian-feng Chen
1Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
Zhonghua Nei Ke Za Zhi
|April 21, 2005
Summary
Plasma N-terminal pro-B-type natriuretic peptide (Nt-proBNP) levels decrease with heart failure treatment, correlating with clinical improvement. This indicates Nt-proBNP is a valuable biomarker for monitoring treatment effectiveness in heart failure patients.
Area of Science:
- Cardiology
- Biochemistry
- Clinical Medicine
Context:
- Heart failure is a complex clinical syndrome.
- Effective monitoring of treatment is crucial for patient outcomes.
- Biomarkers play a key role in assessing disease status and treatment response.
Purpose:
- To investigate dynamic changes in plasma N-terminal pro-B-type natriuretic peptide (Nt-proBNP) levels during heart failure treatment.
- To correlate these Nt-proBNP level changes with clinical improvements in heart failure patients.
Summary:
- Plasma Nt-proBNP levels were significantly higher in heart failure patients compared to controls.
- Nt-proBNP levels decreased progressively during treatment, mirroring improvements in clinical characteristics.
- Admission Nt-proBNP levels showed a negative correlation with therapeutic response.
Impact:
- Plasma Nt-proBNP serves as a reliable biochemical indicator for long-term monitoring of heart failure patients.
- This study supports the use of Nt-proBNP in clinical practice for assessing treatment efficacy.
- Findings contribute to personalized management strategies for heart failure.